Literature DB >> 16706622

Expansion after epitope peptide exposure in vitro predicts cytotoxic T lymphocyte epitope dominance hierarchy in lymphocytes of vaccinated mamu-a*01+ rhesus monkeys.

Ramu A Subbramanian1, William A Charini, Marcelo J Kuroda, Michael Seaman, Heng Chhay, Michelle A Lifton, Darci A Gorgone, Jörn E Schmitz, Angela Carville, Norman L Letvin.   

Abstract

Because of the importance of developing HIV vaccine strategies that generate cytotoxic T lymphocyte (CTL) responses with a maximal breadth of epitope recognition, we have explored a variety of novel strategies designed to overcome the usual propensity of CTLs to focus recognition on a limited number of dominant epitopes. In studies of rhesus monkeys expressing the Mamu-A*01 MHC class I allele, we show that variously configured multiepitope plasmid DNA vaccine constructs elicit CTL populations that do not evidence skewing of recognition to dominant epitopes. Nevertheless, repeated boosting of these vaccinated monkeys with different live recombinant vaccine vectors uncovers and amplifies the usual CTL epitope dominance hierarchy. Importantly, in vitro peptide stimulation of peripheral blood mononuclear cells from monkeys that have received only a multiepitope plasmid DNA priming immunization uncovers this dominance hierarchy. Therefore, the dominance hierarchy of the vaccine-elicited epitope-specific CTL populations is inherent in the T lymphocytes of the monkeys after initial exposure to epitope peptides, and the ultimate breadth of epitope recognition cannot be modified thereafter. This finding underscores the enormous challenge associated with increasing the breadth of CTL recognition through vaccination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16706622     DOI: 10.1089/aid.2006.22.445

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  3 in total

1.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Authors:  Paul Spearman; Spyros Kalams; Marnie Elizaga; Barbara Metch; Ya-Lin Chiu; Mary Allen; Kent J Weinhold; Guido Ferrari; Scott D Parker; M Juliana McElrath; Sharon E Frey; Jonathan D Fuchs; Michael C Keefer; Michael D Lubeck; Michael Egan; Ralph Braun; John H Eldridge; Barton F Haynes; Lawrence Corey
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

2.  Clonal focusing of epitope-specific CD8+ T lymphocytes in rhesus monkeys following vaccination and simian-human immunodeficiency virus challenge.

Authors:  Pritha Sen; William A Charini; Ramu A Subbramanian; Edwin R Manuel; Marcelo J Kuroda; Patrick A Autissier; Norman L Letvin
Journal:  J Virol       Date:  2007-10-31       Impact factor: 5.103

3.  Comparison of immunogen designs that optimize peptide coverage: reply to Fischer et al.

Authors:  David C Nickle; Nebojsa Jojic; David Heckerman; Vladimir Jojic; Darko Kirovski; Morgane Rolland; Sergei Kosakovsky Pond; James I Mullins
Journal:  PLoS Comput Biol       Date:  2008-01       Impact factor: 4.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.